Alkermes Announces Priority Review by FDA for VIVITROL(R) for Opioid Dependence

Alkermes, Inc. today announced that the supplemental New Drug Application (sNDA) for VIVITROL(R) (naltrexone for extended-release injectable suspension) for opioid-dependence has been designated a priority review by the U.S. Food and Drug Administration (FDA).

Read more ›